German drugmaker Boehringer Ingelheim and privately-held 3T Biosciences have entered into a strategic collaboration and licensing agreement to discover and develop new cancer therapies.
The partnership will bring together the US biotech company’s 3T-TRACE discovery platform with Boehringer’s two-pronged research strategy combining cancer cell-directed and immune cell-targeting compounds.
"3T’s 3T-TRACE discovery platform has the potential to transform the treatment of cancers and beyond"
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze